Proxies for the presence or likelihood of an adaptive immune response, including tumour mutational burden, PD-L1 expression, various signatures of inflammatory gene expression, and biomarkers based on mIHC or mIF have all been correlated with response to anti-PD-1 or PD-L1 therapy, with a recent meta-analysis by Lu et al. The gene discussed is CD274; the disease is neoplasm.